Clare Simpson 21 st November Content courtesy of Steve Jones, Paul Illot, Bert Frohlich, Thomas Ryll Biopharm Services
|
|
- Alexander Johnson
- 6 years ago
- Views:
Transcription
1 Modelling a technology roadmap for acceleration of global industry innovation Presentation to Wales Life Science Hub, Health Economics Special Interest Group Clare Simpson 21 st November 2016 Content courtesy of Steve Jones, Paul Illot, Bert Frohlich, Thomas Ryll Biopharm Services
2 Who is BioPhorum Operations Group (BPOG) Industry collaboration that brings together 33 biomanufacturers, collaborating in six phorums to accelerate the industry 2
3 6 Phorums covering all aspects of operations and accelerating biopharma industry s journey to maturity Supply Partner Phorum Drug Substance Development Group Fill Finish Information Technology Technology Road Map BPOG manages the linkages to ensure Decisions are made at the right time, at the right place by the right people Linkages are made visible to avoid redundancy Synergies are leveraged through effective coordination Drug Substance, Fill Finish, Development Group and IT Phorums Accelerate the way the industry delivers near term results making best practice development and implementation faster, cheaper and smarter Supply Partner Phorum Strategic focus on the wider supply chain needs of the industry; defining, developing & implementing solutions Focus on business processes/systems & culture The focus for this presentation Revolutionise the way the industry develops longer term transformational manufacturing and technology capabilities Focus on longer term strategy & 10+yr time horizon, defining needs, difficult challenges and potential solutions Regulatory Interactions Group Engage and align with Health Agencies in the design and adoption of advances in manufacturing 3
4 What is a Technology Road Map?! An industry technology roadmap is a dynamic and evolving collaborative technology management process For: determining precompetitive critical needs and drivers, identifying technology and/or manufacturing targets, and assessing/modeling potential solutions 4
5 Overview of Methodology for Technology Roadmap Construction 1 Evaluate Biopharmaceutical Market Trends Define Objectives 2 3 Identify Main Business Drivers & Metrics Develop Representative Scenarios 4 Define Scenario/Options Matrix and Objectives Business Scenarios (Key Drivers) vs. Biomanufacturing Facility Type Scenarios (Options) Model 5 Model Facility Types Fix: Process/Facility Type Vary: Throughput, utilization, product mix Model Business Scenarios Fix: Throughput, Product mix Vary: Process/facility design Analyze 6 7 Identify/prioritize Opportunities for Improvement Identify Potential Solutions and Alternatives Identify/prioritize Advantages / disadvantages Identify Potential Solutions and Alternatives Plan 8 Define Development Timelines and Pathways Define Development Timelines and Pathways Technology Roadmap 5
6 Developing Representative Scenarios (Step 3) Purpose of Business Scenarios To help evaluate biomanufacturing strategies and technologies that will have greatest impact for a particular set of business drivers Not all companies have the same set of Key business drivers or metrics Purpose of Biomanufacturing / Facility Type Scenarios and Options Represent today s typical facilities (current state-of-art) Many companies have existing assets that need to be utilized and even potentially expanded Serve as starting point for technology road map 6
7 Defining Objectives and Options for Modeling (Step 4) Purpose of Modeling Identify areas of opportunity for improvement within a given scenario / facility type. Compare performance between options within a scenario or between scenarios relative to a given metric o e.g. compare estimated Cost of Goods using different process formats Process parameter sensitivity analysis Identify bottlenecks in throughput and breakpoints in technology strategy/selection. To evaluate the technology improvements proposed by the roadmap teams Model developed in collaboration with Biopharm Services, using Biosolve tool Limitations of Current Models Performance estimates are not absolute. Models are not calibrated to any specific circumstance such as location or specific organizational context For relative comparisons only; Default values for base line comparison (e.g. price of raw material costs, equipment and labor, installation factors Excluded Site purchase, staffing cost and raw materials & consumables up to production Central development labs and site offices Site warehousing Black utilities 7
8 Net Present Cost: Scaling up vs. Scaling Out. Expanded or Multi-Facility 6 x 2,000L Single-use Bioreactors Conventional Six-pack Facility 6 x 15,000L Stainless Steel Bioreactors Model developed in collaboration with Biopharm Technology Services, Roadmapping using Biosolve tool Total Facility Output (kg/yr) 8
9 Business drivers Driver Metric Description 5 yr Target 10 yr Target Cost Total cost to supply COGs - Labour, materials, utilities, variable costs, delivery rejects. $50/gm (mabs) $10/gm (mabs) Speed Cost of upfront investment in manufacturing Reduction of total cost to supply from 2015 values 50% 90% Total capital cost of facility to supply 1,000,000 doses / year $100M DS facility $50M DP facility $50m DS facility $25M DP facility Cost of development Start of phase 3 process analytical formulation development to launch (1st major market approval) - reduction from 2015 levels 25% 75% Time to make product (End to end Time from initiating Drug Substance Production (vial thaw) to completing speed) Drug Product Production 2 months 1 month Time from initiating Drug Substance Production (vial thaw) to completing DP Production - reduction from 2015 levels 50% 75% Time to release product (End to Time from completion of Drug Product production to full release of Drug end speed) Product 2 weeks 1 day Time to produce first GMP material for the clinic Time from DNA (molecule selection) to material available to clinic 12 months 8 months Speed to market Time from release of phase 1 material to launch 5 years 3 years Time to introduce a change to an existing process Time to introduce a process change (specifically new DS site, new resin, etc) 2 months 1 month Time to introduce a process change (eg new DS site, new resin, etc) 18 months 6 months Facility build speed Time from build decision to ready for first PPQ batch 2 years 1 year The ability to change to different platforms (eg, CHO, E. coli, yeast, gene Flexibility Number of platforms per suite therapy) within a suite. 3 >5 Titer Range in upstream that is The ability to manage higher and wider titer ranges in both fed-batch (FB) FB: 1 10g/L FB: 2-40g/L directly accommodated by and perfusion (P). P: 0.5-5g/L/day P: g/L/day downstream facility fit Facility production per unit time - Time facility in use for production (rather than product changeover, Utilization percentage cleaning, shutdown / maintenance) >85% >95% Discard rate, investigation resources. Quality Cost of Non-Quality Batch record rework. Includes RMs 10% of operating costs 2% of operating costs Assay quality Process Variability Product availability Measure of process reliability. PPK for assay for all measures (release tests, CQAs, CPPs) Inventory level >1.5 >1.8 50% reduction 2 months 90% reduction 2 weeks March
10 Conclusions and Next steps Significant progress has been made in bringing the industry together for this precompetitive collaboration A work in progress, More work to be done Will take some time and a few iterations. First time this is being done with wide industry participation Vendor and academic partner participation Technology innovation opportunities are beginning to be identified More modeling to be done to help assess value and prioritize Plan to publish completed road map before mid of
11 Thank You! Disclaimer This presentation was prepared by the BPOG Consortium. The opinions and views expressed are from the BPOG Consortium and do not reflect the views of individual member companies 11
12 Anti-Trust Compliance Statement v4.0 It is the clear policy of BioPhorum that Biophorum and its members will comply with all relevant anti-trust laws in all relevant jurisdictions All BioPhorum meetings and activities shall be conducted to strictly abide by all applicable antitrust laws. Meetings attended by BioPhorum members are not to be used to discuss prices, promotions, refusals to deal, boycotts, terms and conditions of sale, market assignments, confidential business plans or other subjects that could restrain competition. Anti-trust violations may be alleged on the basis of the mere appearance of unlawful activity. For example, discussion of a sensitive topic, such as price, followed by parallel action by those involved or present at the discussion, may be sufficient to infer pricefixing activity and thus lead to investigations by the relevant authorities.. Criminal prosecution by federal or state authorities is a very real possibility for violations of the antitrust laws. Imprisonment, fines or treble damages may ensue. BioPhorum, its members and guests must conduct themselves in a manner that avoids even the perception or slightest suspicion that antitrust laws are being violated. Whenever uncertainty exists as to the legality of conduct, obtain legal advice. If, during any meeting, you are uncomfortable with or questions arise regarding the direction of a discussion, stop the discussion, excuse yourself and then promptly consult with counsel.. The antitrust laws do not prohibit all meetings and discussions between competitors, especially when the purpose is to strengthen competition and improve the working and efficiency of the marketplace. It is in this spirit that the BioPhorum conducts its meetings and conferences. 12
Enhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies. 06 February 2018
Enhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies 06 February 2018 Overview Single-use technology (SUT) is a rapidly evolving technology that focuses on
More informationA Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example
A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationRobert Posgai Director of Materials Procurement, Biogen (BPOG)
Keynote Speaker Building the Foundations for Excellence in Biopharmaceutical Raw Material Supply Chain and Impact of Modality on Excipient Expectations Robert Posgai Director of Materials Procurement,
More informationWhat prompts over 100
B i o P r o c e s s EXECUTIVE BioPhorum Operations Group Technology Roadmap, Part 1 Four Trends Shaping the Future of the Industry Steve Jones What prompts over 100 biopharmaceutical manufacturers, leading
More informationBioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future
Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems Jonathan Romero CMC Leadership, Technical Development Pharmaceutical Operations & Technology 2015 ISPE PRODUCT SHOW Business Drivers Elements
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationAlthough great strides have
FOCUS ON... INNOVATION BioPhorum Operations Group Technology Roadmapping, Part 3 Enabling Technologies and Capabilities Bob Brooks, Jonathan Dakin, Clare Simpson, and Linda Wilson Although great strides
More informationA holistic regulatory approach to accelerated CMC development
A holistic regulatory approach to accelerated CMC development Seán Barry Ph.D Pharmaceutical Assessor Health Products Regulatory Authority CMC Strategy Forum 2017 Disclaimer: The opinions expressed are
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationEfficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs
Efficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs Thomas C. Ransohoff and Howard L. Levine, Ph.D. BioProcess Technology Consultants Inc. Presented at IBC
More informationSEEING THE FUTURE A REVIEW OF THE ISPE 2016 FACILITY OF THE FUTURE CONFERENCE. Phil McDuff VP Global Engineering Biogen
SEEING THE FUTURE A REVIEW OF THE ISPE 2016 FACILITY OF THE FUTURE CONFERENCE Phil McDuff VP Global Engineering Biogen Robert Chew President & CEO Commissioning Agents Inc. Jim McGlade Client Leader BHDP
More informationKelly Thom Associate Principal Scientist Fujifilm Diosynth Biotechnologies. Your Biologics and Vaccines CDMO Partner of Choice.
Process Design for an All Single-Use Manufacturing Facility: Scaling Low to High Titer Processes to Fit Standard mab Equipment BioProcess International West March 2, 2017 Kelly Thom Associate Principal
More informationPrioritizing and Managing Key CMC Elements
Prioritizing and Managing Key CMC Elements Using 21 st Century Principles during Early Development Laurie Graham Product Quality/CMC Reviewer FDA/CDER/OPS/OBP Division of Monoclonal Antibodies 1 Disclaimer
More informationPHARMA CATCHES ON TO CONTINUOUS MANUFACTURING
01 PHARMA CATCHES ON TO CONTINUOUS MANUFACTURING Support from the FDA, industry groups and automation suppliers is helping pharmaceutical companies break the batch habit in favor of a continuous approach
More informationFast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing
GE Healthcare Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing A case study Fast Trak Services Long-term collaboration supports speed to market in single-use
More informationISPE: Pharma Industry Outlook
ISPE: Pharma Industry Outlook ANDREW D. SKIBO Head of Global Biologics Operations & Global Engineering MedImmune/AstraZeneca Chairman, ISPE Board of Directors October 7, 2015 Linking Past ISPE Drivers
More informationStrategic Considerations for Manufacturing Process Development
Strategic Considerations for Manufacturing Process Development PDA Israel Key areas for strategic drug development planning Ramat Gan, 24th Oct 2018 Oren Hesrhkovitz GM, Opko Biologics Presentation Overview
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationFast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China
GE Healthcare Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China A case study Fast Trak Services Ongoing collaboration aims to accelerate biosimilar approval in China
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationCHO-GSN PLATFORM STABLE CELL LINE GENERATION. NR v5
CHO-GSN PLATFORM STABLE CELL LINE GENERATION NR3160 20180122 v5 Highlights of LakePharma s CHO-GSN Cell Line Platform 2 LakePharma proprietary technology Complete cell line lineage and clear path to commercialization,
More informationAntitrust Compliance Guidelines. Approved by the PODS Board of Directors April 21, 2011
Antitrust Compliance Guidelines Approved by the PODS Board of Directors April 21, 2011 PODS Antitrust Compliance Guidelines One of the major goals of the Pipeline Open Data Standard Association (PODS)
More informationFuture biologics manufacturing
Future biologics manufacturing Process integration with single-use technology Dr. Günter Jagschies Senior Director, Strategic Customer Relations GE Healthcare Life Sciences Uppsala, Sweden Mammalian Cell
More informationCONTINUED PROCESS VERIFICATION (CPV) INFORMATICS SYSTEMS AND VALIDATION
CONTINUED PROCESS VERIFICATION (CPV) INFORMATICS SYSTEMS AND VALIDATION OUTPUT FROM BIOPHORUM OPERATIONS GROUP (BPOG) COLLABORATION OF BIOTECH COMPANIES Carly Cox, Process Informatics Manager, Pfizer on
More informationINTERNATIONAL DIGITAL PUBLISHING FORUM ANTITRUST COMPLIANCE POLICY AND GUIDELINES
INTERNATIONAL DIGITAL PUBLISHING FORUM ANTITRUST COMPLIANCE POLICY AND GUIDELINES It is the policy of the International Digital Publishing Forum ("IDPF" or "the Forum") to comply with all antitrust and
More informationMitigating Commercial Risks in Continuous Manufacturing Drug Product
Mitigating Commercial Risks in Continuous Manufacturing Drug Product Ian Leavesley Eli Lilly Indianapolis, Indiana Commercializing Continuous Processing in Pharma Boston, MA Jan 30 th Feb 1 st 2017 Outline
More informationBIOMANUFACTURING TECHNOLOGY ROADMAP
BioPhorum Operations Group Ltd BIOMANUFACTURING TECHNOLOGY ROADMAP BPOG Technology Roadmap 1 Acknowledgments The following member company participants are acknowledged for their efforts and contributions
More informationContinuously Improving Bioprocesses: Biopharmaceutical Capabilities
Continuously Improving Bioprocesses: Biopharmaceutical Capabilities Pall Corporation A Legacy of Innovation Dr. David B. Pall Founded by Dr. David B. Pall in 1946, Pall Corporation has grown from a company
More informationPharma&Biotech. Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies
Pharma&Biotech Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies Elise-marie R. Beri / Lonza Seng Biologics /, Basel Inc / 10.
More informationOptimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.
Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk Feng Gao, MD, PhD AutekBio CO. Expression Systems used for Approved Antibody and Antibody-Related
More informationLFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING
YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING COMMITMENT AND FLEXIBILITY LFB BIOMANUFACTURING is a medium-sized CDMO offering Bioproduction services, from an industrial facility
More informationManaging Demand Uncertainty in Biologics Production
Managing Demand Uncertainty in Biologics Production By Stephen Lam, senior vice president, head of biologics, and John Ward, vice president of engineering, Patheon When a biologics company prepares to
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationAssessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development
Assessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development and Supply Our Mission To discover, develop and deliver
More informationDeveloping the Control Strategy for Enhanced Testing and Continuous Monitoring
Developing the Strategy for Enhanced Testing and Continuous Monitoring i Graham Tulloch, PhD Research Advisor BioProcess Research and Development Outline Introduction Regulatory environment strategy t
More informationEconomic Impact of Single-Use Bioreactors
Economic Impact of Single-Use Bioreactors Rick Stock 2012 BIO International Convention BioProcess Theater Presentation Upstream Processing Boston, MA June 19th, 2012 BioProcess Technology Consultants www.bptc.com
More informationOFFICE OF THE GENERAL COUNSEL ANTITRUST COMPLIANCE BOOKLET
OFFICE OF THE GENERAL COUNSEL ANTITRUST COMPLIANCE BOOKLET NOVEMBER 2017 CONTENTS INTRODUCTION... 3 THE IMPORTANCE OF OBEYING THE ANTITRUST LAWS... 3 A SNAPSHOT PICTURE OF ANTITRUST LAW... 3 A. PER SE
More informationTHE AMERICAN INSTITUTE OF ARCHITECTS ANTITRUST COMPLIANCE GUIDELINES
THE AMERICAN INSTITUTE OF ARCHITECTS ANTITRUST COMPLIANCE GUIDELINES Introduction The American Institute of Architects and its members are committed to full compliance with all laws and regulations, and
More informationImproving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns
Improving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns Michael Dittmer MedImmune, BioProcess Engineering BPI West, San Francisco, CA March 2 nd, 2017 Outline Motivation
More informationSINGLE USE SYSTEMS IN NEXT-GEN BIOLOGICS DRUG SUBSTANCE MANUFACTURING
JUNE 21, 2018 SINGLE USE SYSTEMS IN NEXT-GEN BIOLOGICS DRUG SUBSTANCE MANUFACTURING GANESH VEDANTHAM PROCESS DEVELOPMENT MODALITIES IN THE AMGEN PORTFOLIO 2 AMGEN IS EVOLVING OPERATIONS CAPABILITIES TO
More informationLentiviral Vector Manufacturing Challenges and Solutions
Lentiviral Vector Manufacturing Challenges and Solutions Bo Kara Cell Gene Therapy CMC Elizabeth and Patience Save the Children clinic attendee Liberia Photo credit Martin Web/Save the Children Strategy:
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationBrazil: A Global Biotech Hub
Brazil: A Global Biotech Hub Single Use Devices Enables Bioprocessing for Domestic Biologics, Biosimilars, Export Mathew Cherian Ph.D. Director Pharmaceutical Development Hospira, Inc. USA Brazil s Potential
More informationAntitrust and You: Antitrust Compliance Procedures
Antitrust and You: Antitrust Compliance Procedures Objective The American Gas Association (AGA) and its member companies are committed to full compliance with all laws and regulations, and to maintaining
More informationProcess economic simulation for scalable production of adenovirus
Process economic simulation for scalable production of adenovirus This application note discloses process economic modelling of a modern start-to-finish adenovirus production process. The novel process
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationTABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5
TABLE OF CONTENTS Chapter 1: EXECUTIVE SUMMARY 1.1 Introduction 1-1 1.2 Participants Locations 1-3 1.3 Industry Pricing Trends 1-4 1.3.1 Recent Industry Pricing Changes 1-4 1.3.2 Contractor Utilization
More informationProduct Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients
Product Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients Dafni Bika, Jennifer Walsh and Tara Nestor Global Manufacturing Science and Technology Bristol-Myers
More informationTim Moore Global Head, Pharmaceutical Technical Operations Biologics, Genentech a member of the Roche Group
Ensuring the Supply of Quality Biopharmaceuticals: Integrated Manufacturing Network & Continual Improvement of Manufacturing Process Tim Moore Global Head, Pharmaceutical Technical Operations Biologics,
More informationCSL s Large Scale Cell Culture Facility
BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility
More informationTHE AMERICAN INSTITUTE OF ARCHITECTS ANTITRUST COMPLIANCE STATEMENT AND PROCEDURES
THE AMERICAN INSTITUTE OF ARCHITECTS ANTITRUST COMPLIANCE STATEMENT AND PROCEDURES September 2002 The American Institute of Architects 1735 New York Avenue, NW Washington, DC 20006 AIA Info Central (800)
More informationPPQ-to-Approval Timelines Acceleration Approaches at BMS
PPQ-to-Approval Timelines Acceleration Approaches at BMS Marcus Boyer Bristol-Myers Squibb Associate Director Process Life-cycle Management Syracuse, NY USA Kristen Manchester Bristol-Myers Squibb Sr.
More informationINTEGRATED PRODUCTION PLATFORMS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME PROCESS DEVELOPMENT, SCALE UP, GMP-COMPLIANT PRODUCTION AND CONSULTING INTEGRATED PRODUCTION PLATFORMS EVERYTHING STARTS WITH YOUR BRILLIANT
More informationGE Intelligent Platforms. Operational Excellence
GE Intelligent Platforms Operational Excellence Drive Operational Excellence in manufacturing Continuous improvements in key areas of your operations can help you reduce manufacturing costs, protect profit
More informationTrends in capacity utilization for therapeutic monoclonal antibody production
[mabs 1:2, 151-156; March/April 2009]; 2009 Landes Bioscience Report Trends in capacity utilization for therapeutic monoclonal antibody production Eric S. Langer President and Managing Partner; BioPlan
More informationBIOMANUFACTURING TECHNOLOGY ROADMAP
BioPhorum Operations Group Ltd BIOMANUFACTURING TECHNOLOGY ROADMAP BPOG Technology Roadmap 1 Acknowledgments The following member company participants are acknowledged for their efforts and contributions
More informationDeveloping a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods
Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility,
More informationUpstream mammalian cell processing challenges and prospects
BioProcess International Berlin, April 11-14, 2005 Upstream mammalian cell processing challenges and prospects John Birch Lonza Significance of Mammalian Cell Processes Commercial significance of biopharmaceutical
More informationPPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 W. BRYAN SILVEY W. Bryan Silvey is the Senior Director, Global Regulatory Affairs/CMC for Baxalta US Inc. He is located at Baxalta s Westlake Village California regional
More informationGlobal Biological Production Summit
Global Biological Production Summit 12./13. December 2016 San Diego Timo Simmen Director Technical Operations Parenterals Platform Janssen Supply Chain Environment is changing «The world is changing»
More informationEnhancing Product Quality through CM An Industry Perspective for Transitioning CM from Technology Evaluation to a Default Manufacturing Platform
Enhancing Product Quality through CM An Industry Perspective for Transitioning CM from Technology Evaluation to a Default Manufacturing Platform Ahmad Almaya Lilly Research Laboratories Eli Lilly and Company
More informationOverview Rentschler Biotechnologie
Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we
More informationApplication of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols
Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationINTERNATIONAL SECURITIES ASSOCIATION FOR INSTITUTIONAL TRADE COMMUNICATION ANTITRUST COMPLIANCE POLICY
INTERNATIONAL SECURITIES ASSOCIATION FOR INSTITUTIONAL TRADE COMMUNICATION 1.0 Antitrust Compliance Policy ANTITRUST COMPLIANCE POLICY The policy of the International Securities Association for Institutional
More informationKupers Luc IMI webinar
Biomanufacturing 2020 (biomfg2020): Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes Kupers
More informationAccelerated Development for Biopharmaceutical Products. Josh Grieco February 5th, 2018
Accelerated Development for Biopharmaceutical Products Josh Grieco February 5th, 2018 Overview Accelerated development drivers CMC development considerations Case Study Early Investment in Process Performance
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationSD ASSOCIATION ANTITRUST POLICY AND GUIDELINES
SD ASSOCIATION ANTITRUST POLICY AND GUIDELINES The purpose of this Antitrust Policy and Guidelines is to provide a brief overview of the antitrust and competition laws applicable to the SD Association
More information10 years of biomanufacturing: Industry maturity shown in the shifts toward process improvement
10 years of biomanufacturing: Industry maturity shown in the shifts toward process improvement Bioprocess International Anne Montgomery ~1500 words, 2 graphs. The biopharmaceutical industry is emerging
More informationThe Process Diagnostic. How to optimize the technology transfer and the development
The Process Diagnostic How to optimize the technology transfer and the development a does the on Introduction A critical aspect of industrialization is development. It is all about how to industrialize
More informationSeamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson
Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson Senior Management Consultant Agenda Introduction A state-of
More informationEXPANDING PRODUCTION AT BIOLOGICS FACILITIES: EFFECTIVE STRATEGIES AND PLANNING. Biomanufacturing Conference June Ken Hamilton, Genentech
EXPANDING PRODUCTION AT BIOLOGICS FACILITIES: EFFECTIVE STRATEGIES AND PLANNING Biomanufacturing Conference June 27-28 2013 Ken Hamilton, Genentech AGENDA Business Drivers Strategic Considerations Business
More informationTowards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned
Case studies in process intensification Towards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned March 14, 2017 San Diego, California Adam Goldstein, Oliver Molina, Michelle
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationMaximizing the potential of manufacturing data to advance biopharmaceutical production
Maximizing the potential of manufacturing data to advance biopharmaceutical production Anja Zgodic 1 Ashley Lee, Paul Stey, Andras Zsom, Sam Bell 2 Tom Mistretta, Patrick Gammell 1 1. Amgen Process Development
More informationSingle-use technology and sustainability: quantifying the environmental impact
Single-use technology and sustainability: quantifying the environmental impact Bill Flanagan Director, Ecoassessment Center of Excellence, GE 1 November 2016 Imagination at work Agenda Biopharmaceutical
More informationProcess Robustness & Challenges to Demonstrating Compliance
Process Robustness & Challenges to Demonstrating Compliance Nick Smith Head of Production & TSS 2 nd March 2017 95% Thomas Eldered 5% Management Headcount : 270 3 GMP facilities Cobra s Structure Cobra
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationDisposable Technology - a technobusiness perspective
Disposable Technology - a technobusiness perspective A Business Briefing being held on 10th March 2011 With Mrs Miriam Monge, VP Marketing Biopharm Services, Chairs: Prof Gary Lye and Prof Eli Keshavarz-Moore,
More informationEstablished May 1, 2001, revised April 4, 2011
Established May 1, 2001, revised April 4, 2011 Introduction - What is the? The sets the standards of behavior for Company directors and employees. By following the code, we conduct activities in compliance
More informationspeeding medicines to people Potential Benefits of PAT for Biomanufacturing IFPAC 2005
speeding medicines to people Potential Benefits of PAT for Biomanufacturing IFPAC 2005 Outline PAT for Biologics (Biotherapeutics) Mfg. What is a biotherapeutic? Converging trends in Biotech PAT player
More informationThermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production
Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production May/June 2013 1 The world leader in serving science Agenda
More informationA GUIDE TO BIOMANUFACTURING AT GENZYME
M A K I N G P R O T E I N T H E R A P I E S A GUIDE TO BIOMANUFACTURING AT GENZYME Genzyme strives to make a life-changing difference for patients with serious diseases by discovering, developing, and
More informationA TECHNOLOGY ROADMAP PROCESS TO TRANSFORM THE BIOPHARMACEUTICAL MANUFACTURING INDUSTRY: KNOWLEDGE MANAGEMENT HIGHLIGHTS
A TECHNOLOGY ROADMAP PROCESS TO TRANSFORM THE BIOPHARMACEUTICAL MANUFACTURING INDUSTRY: KNOWLEDGE MANAGEMENT HIGHLIGHTS Beth Junker, BioProcess Advantage LLC Accelerating Biopharmaceutical Development
More informationBPI.Seminar Semina opelmg ropelmg.com com
Send questions to: BPI.Seminars@propelmg.com Moving to the next level of Manufacturing Oct 14 th 2009 BPI Raleigh Rolf Douwenga VP Global Research and Development DSM Biologics. DSM CONFIDENTIAL FL15 Agenda
More informationDeveloping Integrated Quality Criteria to Continuously Improve the Supply Chain Process
Developing Integrated Quality Criteria to Continuously Improve the Supply Chain Process E. D. Fassoula (1), N. Bilalis (2), and V.S. Moustakis (2,3) (1) NEOSET S.A. Vasiliko Chalkis Chalkis, GR-340 02
More informationTrends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International
Trends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International Single-use/disposable bioprocessing equipment has come to thoroughly dominate
More informationMay 16-18, 2011 Beijing, China. Mark Rosolowsky, Ph.D. Vice President, Bristol-Myers Squibb
What You Should Know When You Make Manufacturing Changes to Biotechnology Products May 16-18, 2011 Beijing, China Mark Rosolowsky, Ph.D. Vice President, Global Regulatory Sciences-CMC Bristol-Myers Squibb
More informationLIVING OUR CORE VALUES. Supplier Code of Conduct
LIVING OUR CORE VALUES Supplier Code of Conduct Introduction to Our Supplier Code of Conduct Chesapeake Energy is committed to living our core values of integrity and trust, respect, transparency and open
More informationPreparing for CECL. How Community Banks Can Prepare for Implementation
Preparing for CECL How Community Banks Can Prepare for Implementation Changes in the accounting and reporting of credit risk have been in the works since the financial crisis, but that doesn t make adopting
More informationFast Trak Services from molecule to market
GE Healthcare Fast Trak Services from molecule to market OPEN At the speed of Fast Trak Whether you re looking to launch a new molecule, enhance existing capacity, or bring biosimilars to emerging markets,
More informationTransition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics
A Virtual Think Tank Executive Summary Transition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics By: Unmesh Lal, Program Manager, Transformational
More information"Value Stream Mapping How does Reliability play a role in making Lean Manufacturing a Success " Presented by Larry Akre May 17, 2007
"Value Stream Mapping How does Reliability play a role in making Lean Manufacturing a Success " Presented by Larry Akre May 17, 2007 LAKRE 2007 1 Lean Manufacturing What is Lean Manufacturing? A philosophy
More informationHealthcare Predictions for Executives and Strategists
Strategic Planning, M. Duncan, J. Gabler, J. Young, J. Klein Research Note 9 December 2002 Healthcare Predictions for Executives and Strategists Business and IS executives as well as business and IS managers
More informationAdaptDose, an innovative platform that reduces product development time and costs by 30% or more
WHITE PAPER January 2017 AdaptDose, an innovative platform that reduces product development time and costs by 30% or more Frontida BioPharm, Inc. Ron Connolly 01.01.2017 CONTENTS ABSTRACT INTRODUCTION
More informationInspiring Advances in Bioprocessing. John Bonham-Carter March 14, 2017
Inspiring Advances in Bioprocessing John Bonham-Carter March 14, 2017 Bioprocessing Trends Emerging trends, new challenges Integrated continuous processing Upstream continuous processing (perfusion) proven
More information